VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 130 participants.

Also called NCT06249165

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 130 participants (enrolled count) (from the registry)
Sponsor
  • Duke University Registry lists this organization as the lead sponsor
  • Novartis Registry lists this organization as a collaborator
Registry
  • NCT NCT06249165
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06249165. Randomized; no masking; primary purpose treatment. Start 2024-12-16 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
Acronym
V-INCLUSION
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
Inclisiran
Lead sponsor
Duke University (class: other)
Collaborator
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06249165
Content hash
8ab2303f1e6397b10ce27199710f0e3008d84bc0a3e236256ca5cdc9d1c660e6